Acute Myeloid Leukemia (AML)
Symptoms, Doctors, Treatments, Advances & More

Acute Myeloid Leukemia (AML) Overview

Save information for later
Sign Up

Learn About Acute Myeloid Leukemia (AML)

View Main Condition: Leukemia

What is the definition of Acute Myeloid Leukemia (AML)?
Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor.
Who are the top Acute Myeloid Leukemia (AML) Local Doctors?
Elite in Acute Myeloid Leukemia (AML)
Dr. Vijaya R. Bhatt
Hematology | Oncology
Elite in Acute Myeloid Leukemia (AML)
Dr. Vijaya R. Bhatt
Hematology | Oncology
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
402-559-5600
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vijaya Bhatt is a Hematologist and an Oncologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 18 years. Dr. Bhatt is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Elite in Acute Myeloid Leukemia (AML)
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Elite in Acute Myeloid Leukemia (AML)
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute, Adult Leukemia Program

450 Brookline Avenue, 
Boston, MA 
617-632-2214
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Stone is a Hematologist Oncology specialist and a Hematologist practicing medicine in Boston, Massachusetts. Dr. Stone is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Stone is board certified in Hematology, Internal Medicine, and Medical Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Acute Myeloid Leukemia (AML)
Dr. Marina Konopleva
Hematology
Elite in Acute Myeloid Leukemia (AML)
Dr. Marina Konopleva
Hematology
Referral may be required

Montefiore Medical Center

111 East 210th Street, 
Bronx, NY 
718-920-4321
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marina Konopleva, MD, Phd, is Professor, Oncology, Professor, Molecular Pharmacology, Director, Leukemia Program and Co-Director, Blood Cancer Institute, at Montefiore Einstein. Her clinic focus centers on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemia. She has additional expertise in treating patients with high-risk myelodysplastic syndrome and chronic myeloid leukemia. Dr. Konopleva is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

View All Doctors
What are the latest Acute Myeloid Leukemia (AML) Clinical Trials?
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Drug, Biological, Device
Study Phase: Phase 1

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Who is this study for: Child to young adult patients with Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Other, Drug
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone
Study Phase: Phase 3

Summary: This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing t...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center